ATORVASTATIN CALCIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Atorvastatin Calcium, and what generic alternatives are available?
Atorvastatin Calcium is a drug marketed by Accord Hlthcare, ACI, Agnitio, Alkem Labs Ltd, Anbison Lab, Apotex Inc, Biocon Pharma, Cadila Pharms Ltd, Dr Reddys, Dr Reddys Labs Ltd, Graviti Pharms, Hetero Labs Ltd V, Invagen Pharms, Lannett Co Inc, Laurus, Lepu Pharm, Lupin Ltd, Mankind Pharma, Micro Labs Ltd India, MSN, Mylan Pharms Inc, Perrigo R And D, Sandoz Inc, Sciegen Pharms Inc, Sun Pharm Inds Ltd, Teva Pharms, Teva Pharms Usa, Umedica, and Zydus Pharms. and is included in thirty NDAs.
The generic ingredient in ATORVASTATIN CALCIUM is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atorvastatin Calcium
A generic version of ATORVASTATIN CALCIUM was approved as atorvastatin calcium by SUN PHARM INDS LTD on November 30th, 2011.
Summary for ATORVASTATIN CALCIUM
US Patents: | 0 |
Applicants: | 29 |
NDAs: | 30 |
Finished Product Suppliers / Packagers: | 59 |
Raw Ingredient (Bulk) Api Vendors: | 85 |
Clinical Trials: | 69 |
Patent Applications: | 6,390 |
Formulation / Manufacturing: | see details |
Drug Sales Revenues: | Drug sales revenues for ATORVASTATIN CALCIUM |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ATORVASTATIN CALCIUM |
What excipients (inactive ingredients) are in ATORVASTATIN CALCIUM? | ATORVASTATIN CALCIUM excipients list |
DailyMed Link: | ATORVASTATIN CALCIUM at DailyMed |
Recent Clinical Trials for ATORVASTATIN CALCIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
United States Department of Defense | Phase 2 |
University of California, San Francisco | Phase 2 |
Himayat Ullah | N/A |
Pharmacology for ATORVASTATIN CALCIUM
Drug Class | HMG-CoA Reductase Inhibitor |
Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Medical Subject Heading (MeSH) Categories for ATORVASTATIN CALCIUM
Anatomical Therapeutic Chemical (ATC) Classes for ATORVASTATIN CALCIUM
US Patents and Regulatory Information for ATORVASTATIN CALCIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mankind Pharma | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 217081-004 | Jan 5, 2024 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Teva Pharms | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 078773-003 | May 29, 2012 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Graviti Pharms | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 209912-001 | Jun 18, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |